Lineage Cell Therapeutics, Inc. (LCTX) Financials

LCTX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 106.2 million 46.4 million
March 31, 2026 109.5 million 56.8 million
Dec. 31, 2025 112.6 million 69.2 million
Sept. 30, 2025 89.6 million 68.8 million

LCTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -7.2 million 1.6 million
March 31, 2026 -8.1 million 1.2 million
Dec. 31, 2025 -5.0 million 1.1 million
Sept. 30, 2025 -3.6 million 1.2 million

LCTX Net Income

No data available :(

LCTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 50.8 million - 2.3 million
March 31, 2026 53.4 million - 1.5 million
Dec. 31, 2025 55.8 million - 2.4 million
Sept. 30, 2025 40.5 million - 2.6 million

LCTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 261.5 million
March 31, 2026 261.2 million
Dec. 31, 2025 230.1 million
Sept. 30, 2025 228.9 million

LCTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 55000 4.8 million 5.2 million -
March 31, 2026 55000 4.2 million 5.1 million -
Dec. 31, 2025 111000 8.2 million 4.9 million -
Sept. 30, 2025 12000 3.3 million 4.2 million -

LCTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 1.1 million 187000
March 31, 2026 1.7 million 188000
Dec. 31, 2025 6.6 million 66000
Sept. 30, 2025 3.7 million 5000

LCTX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

LCTX

Price: $0.98

52 week price:
0.88
2.09

Payout Ratio Range:
-644.09%
0.42%

Earnings Per Share: -0.19 USD

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 400600

Market Capitalization: 236.2 million

Links: